Cosmo (SWX:CMHC) has just put fresh clinical data in front of investors, reporting that its Phase 2 trial of rifamycin 1% topically acting gel in distal ulcerative colitis achieved the study’s predefined primary endpoint.
Set against this clinical update, Cosmo’s share price has moved to CHF55.40, with a 1-day share price return of 4.14% and a 7-day share price return of 4.73%. However, the year-to-date share price return is down 47.44% and the 1-year total shareholder return has declined 15.85%, while the 3-year total shareholder return of 74.31% points to stronger momentum over a longer horizon than the past five years, where total shareholder return is down 14.41%.
Spot under-the-radar healthcare momentum by comparing Cosmo with other handpicked 123 healthcare AI stocks that are also tying clinical progress to real-world product pipelines.The latest jump in Cosmo’s share price may reflect renewed confidence in the rifamycin program rather than a broad change in sentiment. So how does that move compare with what investors are actually paying today?
Most Popular Narrative: 45% Undervalued
Cosmo last closed at CHF55.40, while the most followed narrative on the stock points to a fair value of CHF100. This gap frames the latest clinical update against a much wider debate about how the portfolio and pipeline are being priced.
The report published by the company on March 6 has caused the share price to fall by 20%, due to the forecast of a decrease in revenues by December 2025 in the absence of a commercial agreement for its new products. This makes me cautious and lower the 3-year growth forecast in the absence of more information.
See why 84 investors see Cosmo as 45% undervalued.
Result: Fair Value of CHF100 (UNDERVALUED)
Still, this relies on licensing deals and late stage trials landing as hoped, and any delay or weak data could quickly challenge the view that the shares are 45% undervalued.
Find out about the key risks to this Cosmo narrative.
Next Steps
Mixed messages in the Cosmo story so far. If you want to move quickly and base your stance on the full picture, weigh both sides through the 2 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Cosmo?
If Cosmo has your attention today, do not stop there. Use this momentum to refresh your watchlist with fresh opportunities that match your style.
- Spot potential mispricings by scanning a focused set of quality opportunities using the 195 high quality undervalued stocks.
- Strengthen your income stream by reviewing companies that feature the 224 dividend fortresses.
- Dial down overall portfolio risk by hunting for resilient businesses via the 223 resilient stocks with low risk scores.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com